慢性肾脏病进展的危险因素及延缓策略

doi:10.3760/cma.j.issn.1007-1245.2024.11.002

摘要/Abstract

摘要：

慢性肾脏病（CKD）是一种病程复杂的慢性疾病，早期往往无症状，随着时间的推移，可导致肾功能障碍并发展为终末期肾病（ESRD），并伴随心血管疾病（CVD）等多种并发症。CKD的易感因素包括性激素、甲状腺激素及家族遗传因素等，疾病发生和进展的危险因素包括肾小球肾炎、高血压、糖尿病、蛋白尿、高脂血症及尿毒素的累积等。目前，CKD治疗目的为减缓其进展和预防CVD，需要开发新的治疗方法来阻止。本文主要对CKD进展的危险因素及延缓策略进行综述。

关键词:

慢性肾脏病, 终末期肾病, 危险因素, 延缓策略, 临床治疗, 进展

Abstract:

Chronic kidney disease (CKD) is a complex disease and is often asymptomatic in the early stages, and can lead to renal dysfunction and progression to end-stage renal disease (ESRD) with a variety of complications, such as cardiovascular disease (CVD) and other complications. Current susceptibility factors for CKD include sex hormones, thyroid hormones, and familial genetic factors, etc. Risk factors for the disease onset and progression include glomerulonephritis, hypertension, diabetes mellitus, proteinuria, hyperlipidemia, and accumulation of urinary toxins. Current CKD treatments aims at slowing the progression of CKD and preventing cardiovascular diseases, so new treatments need to be developed to stop disease progression. This article reviews the risk factors of the progression of CKD and strategies for slowing its progression.

Key words:

Chronic kidney disease, End-stage renal disease, Risk factors, Delay strategy, Clinical treatment, Progress

李昕萌刘倩倩刘云启.

慢性肾脏病进展的危险因素及延缓策略 [J]. 国际医药卫生导报, 2024, 30(11): 1766-1770.

Li Xinmeng, Liu Qianqian, Liu Yunqi.

Risk factors and delay strategies for progression of chronic kidney disease [J]. International Medicine and Health Guidance News, 2024, 30(11): 1766-1770.

参考文献

[1] Ruiz-Ortega M, Rayego-Mateos S, Lamas S, et al. Targeting the progression of chronic kidney disease[J]. Nat Rev Nephrol, 2020,16(5):269-288. DOI: 10.1038/s41581-019-0248-y.
[2] Ortiz A, Sanchez-Niño MD, Crespo-Barrio M, et al. The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem[J]. Nefrologia (Engl Ed), 2019,39(1):29-34. DOI: 10.1016/j.nefro.2018.09.002.
[3] Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J]. Kidney Int Suppl, 2017,7:1-59. DOI: 10.1016/j.kisu. 2017.10.001.
[4] Chapter 3: Management of progression and complications of CKD[J]. Kidney Int Suppl (2011), 2013,3(1):73-90. DOI: 10.1038/kisup.2012.66.
[5] Bikbov B, Perico N, Remuzzi G,et al. Disparities in chronic kidney disease prevalence among males and females in 195 countries: analysis of the global burden of disease 2016 study[J]. Nephron, 2018,139(4):313-318. DOI: 10.1159/000489897.
[6] Valdivielso JM, Jacobs-Cachá C, Soler MJ. Sex hormones and their influence on chronic kidney disease[J]. Curr Opin Nephrol Hypertens, 2019,28(1):1-9. DOI: 10.1097/MNH.0000000000000463.
[7] Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease[J]. Indian J Endocrinol Metab, 2012,16(2):204-213. DOI: 10.4103/2230-8210. 93737.
[8] Katz AI, Lindheimer MD. Renal sodium- and potassium-activated adenosine triphosphatase and sodium reabsorption in the hypothyroid rat[J]. J Clin Invest, 1973,52(4):796-804. DOI: 10.1172/JCI107243.
[9] Huang X, Ding L, Peng K, et al. Thyroid hormones associate with risk of incident chronic kidney disease and rapid decline in renal function: a prospective investigation[J]. J Transl Med, 2016,14(1):336. DOI: 10.1186/s12967-016-1081-8.
[10] Xu X, Eales JM, Akbarov A, et al. Molecular insights into genome-wide association studies of chronic kidney disease-defining traits[J]. Nat Commun, 2018,9(1):4800. DOI: 10.1038/s41467-018-07260-4.
[11] Floege J, Amann K. Primary glomerulonephritides[J]. Lancet, 2016,387(10032):2036-2048. DOI: 10.1016/S0140-6736(16)00272-5.
[12] Flythe JE, Chang TI, Gallagher MP, et al. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference[J]. Kidney Int, 2020,97(5):861-876. DOI: 10.1016/j.kint.2020.01.046.
[13] Lin CY, Hsieh MC, Kor CT, et al. Association and risk factors of chronic kidney disease and incident diabetes: a nationwide population-based cohort study[J]. Diabetologia, 2019,62(3):438-447. DOI: 10.1007/s00125-018-4788-7.
[14] Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review[J]. Am J Kidney Dis, 2018,72(2):267-277. DOI: 10.1053/j.ajkd.2018.03.022.
[15] Li D, Ding J. Molecular mechanism of proteinuria caused progression of chronic renal disease[J]. Beijing Da Xue Xue Bao Yi Xue Ban, 2010,42(5):608-611.
[16] Reiss AB, Voloshyna I, De Leon J, et al. Cholesterol metabolism in CKD[J]. Am J Kidney Dis, 2015,66(6):1071-1082. DOI: 10.1053/j.ajkd.2015.06.028.
[17] Yang Y, Yang Q, Yang J, et al. Angiotensin II induces cholesterol accumulation and injury in podocytes[J]. Sci Rep, 2017,7(1):10672. DOI: 10.1038/s41598-017- 09733-w.
[18] Esgalhado M , Kemp JA , Azevedo R , et al. Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? A pilot randomized controlled trial[J]. Food Funct, 2018,9(12):6508-6516. DOI: 10.1039/c8fo01876f.
[19] Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role?[J]. Nat Rev Nephrol, 2009,5(7):375-383. DOI: 10.1038/nrneph.2009.76.
[20] Cupisti A, Trinchieri A, Lombardi M, et al. Percorso diagnostico-terapeutico per il paziente con calcolosi renale: update 2020 [A diagnostic-therapeutic pathway for patients with kidney stone disease: 2020 update][J]. G Ital Nefrol, 2020,37Suppl 75:2020-S75.
[21] Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update[J]. Am J Kidney Dis, 2020,76 3 Suppl 1:S1-S107. DOI: 10.1053/j.ajkd.2020.05.006.
[22] Cano NJ, Aparicio M, Brunori G, et al. ESPEN guidelines on parenteral nutrition: adult renal failure[J]. Clin Nutr, 2009,28(4):401-414. DOI: 10.1016/j.clnu.2009.05.016.
[23] Kalantar-Zadeh K, Moore LW. Why the Nutritional Management of Acute Versus Chronic Kidney Disease Should Differ[J]. J Ren Nutr, 2019,29(4):265-268. DOI: 10.1053/j.jrn.2019.05.002.
[24] Castro-Barquero S, Arias-Guillén M, Pi-Oriol S, et al. A comparative study of the efficacy of an intervention with a nutritional supplement for patients with chronic kidney disease: a randomized trial[J]. J Clin Med, 2022,11(6):1647. DOI: 10.3390/jcm11061647.
[25] Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology[J]. Nephron Physiol, 2003,93(1):P3-13. DOI: 10.1159/000066656.
[26] Hollenberg NK. Aldosterone in the development and progression of renal injury[J]. Kidney Int, 2004,66(1):1-9. DOI: 10.1111/j.1523-1755.2004.00701.x.
[27] Lytvyn Y, Bjornstad P, Pun N, et al. New and old agents in the management of diabetic nephropathy[J]. Curr Opin Nephrol Hypertens, 2016,25(3):232-239. DOI: 10.1097/MNH.0000000000000214.
[28] Tylicki L, Rutkowski P, Renke M, et al. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation[J]. Am J Nephrol, 2002,22(4):356-362. DOI: 10.1159/000065227.
[29] Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough[J]. Nat Clin Pract Nephrol, 2007,3(9):486-492. DOI: 10.1038/ncpneph0575.
[30] Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med, 2020,383(23):2219-2229. DOI: 10.1056/NEJMoa2025845.
[31] Bakris G, Pergola PE, Delgado B, et al. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study[J]. Hypertension, 2021,78(1):74-81. DOI: 10.1161/HYPERTENSIONAHA.121.17073.
[32] Wada T, Inagaki M, Yoshinari T, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study[J]. Clin Exp Nephrol, 2021,25(2):120-130. DOI: 10.1007/s10157-020-01963-z.
[33] Wan N, Rahman A, Nishiyama A. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease[J]. J Hum Hypertens, 2021,35(2):148-156. DOI: 10.1038/s41371-020-0377-6.
[34] Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters[J]. Physiol Rev, 2011,91(2):733-794. DOI: 10.1152/physrev.00055.2009.
[35] Nespoux J, Vallon V. SGLT2 inhibition and kidney protection[J]. Clin Sci (Lond), 2018,132(12):1329-1339. DOI: 10.1042/CS20171298.
[36] Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019,380(24):2295-2306. DOI: 10.1056/NEJMoa1811744.
[37] Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020,383(15):1436-1446. DOI: 10.1056/NEJMoa2024816.
[38] 郭超花,何晴,邢媛媛. 胰高血糖素样肽1受体激动剂治疗糖尿病肾病的临床研究进展[J]. 国际医药卫生导报,2022,28(21):3106-3108,F4. DOI:10.3760/cma.j.issn.1007- 1245. 2022.21.033.
[39] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016,375(4):311-322. DOI: 10.1056/NEJMoa1603827.
[40] Thomas MC. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes[J]. Diabetes Metab, 2017,43 Suppl 1:2S20-2S27. DOI: 10.1016/S1262-3636(17)30069-1.
[41] Tanaka T, Higashijima Y, Wada T, et al. The potential for renoprotection with incretin-based drugs[J]. Kidney Int, 2014,86(4):701-711. DOI: 10.1038/ki.2014.236.
[42] Kohan DE, Rossi NF, Inscho EW, et al. Regulation of blood pressure and salt homeostasis by endothelin[J]. Physiol Rev, 2011,91(1):1-77. DOI: 10.1152/physrev.00060.2009.
[43] Zanatta CM, Gerchman F, Burttet L, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus[J]. Diabetes Res Clin Pract, 2008,80(2):299-304. DOI: 10.1016/j.diabres.2007.12.024.
[44] Mahajan A, Simoni J, Sheather SJ, et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy[J]. Kidney Int, 2010,78(3):303-309. DOI: 10.1038/ki.2010.129.
[45] Lilitkarntakul P, Dhaun N, Melville V, et al. Risk factors for metabolic syndrome independently predict arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal comorbidity[J]. Diabetes Care, 2012,35(8):1774-1780. DOI: 10.2337/dc11-2345.
[46] Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease[J]. Am J Physiol Regul Integr Comp Physiol, 2016,310(10):R877-884. DOI: 10.1152/ajpregu.00425.2015.
[47] Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial[J]. Lancet, 2019,393(10184):1937-1947. DOI: 10.1016/S0140-6736(19)30772-X.